These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10081126)

  • 1. Cholestasis and liver cell damage due to hypersensitivity to erythromycin stearate--recurrence following therapy with erythromycin succinate.
    Horn S; Aglas F; Horina JH
    Wien Klin Wochenschr; 1999 Jan; 111(2):76-7. PubMed ID: 10081126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases.
    Diehl AM; Latham P; Boitnott JK; Mann J; Maddrey WC
    Am J Med; 1984 May; 76(5):931-4. PubMed ID: 6609640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged cholestasis and disappearance of interlobular bile ducts following chlorpropamide and erythromycin ethylsuccinate. Case of drug interaction?
    Geubel AP; Nakad A; Rahier J; Dive C
    Liver; 1988 Dec; 8(6):350-3. PubMed ID: 3265170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hepatitis caused by various derivatives of erythromycin].
    Funck-Brentano C; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythromycin ethylsuccinate-induced cholestasis.
    Bachman BA; Boyd WP; Brady PG
    Am J Gastroenterol; 1982 Jun; 77(6):397-400. PubMed ID: 6979924
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacokinetics and tolerance of oral erythromycin stearate compared with erythromycin ethylsuccinate: implications for preventing endocarditis.
    Shanson DC; Tidbury P; McNabb WR; Tadayon M
    J Antimicrob Chemother; 1984 Aug; 14(2):157-63. PubMed ID: 6334070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythromycin in acute pharyngitis: a comparison of efficacy and patient tolerance of two twice-daily preparations.
    Guthrie R
    Clin Ther; 1988; 10(5):530-5. PubMed ID: 2856596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the gastrointestinal side effects of two forms of erythromycin.
    Anastasio GD; Robinson MD; Little JM; Leitch BB; Pettice YL; Norton HJ
    J Fam Pract; 1992 Nov; 35(5):517-23. PubMed ID: 1431767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatotoxic syndrome caused by erythromycin ethyl succinate].
    Cocchi P; Silenzi M; Salvi G; Calabri G; Tamburini M; Alvisi P
    Minerva Pediatr; 1982 Jan; 34(1-2):68-9. PubMed ID: 6978458
    [No Abstract]   [Full Text] [Related]  

  • 10. [Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Clinico-immunological demonstration of its allergic origin].
    Cario E; Rünzi M; Becker EW; Gröger G; Ali A; Rehbehn K; Goebell H; Layer P
    Dtsch Med Wochenschr; 1996 Feb; 121(5):129-32. PubMed ID: 8717195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Side effects and complications of antibiotic therapy].
    Zolotarev II; Aslamazov EG
    Urol Nefrol (Mosk); 1974; (1):51-63. PubMed ID: 4374782
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hepatotoxicity due to erythromycin ethylsuccinate].
    Caballeria Rovira E; Arago López JV; Masso Ubeda RM; Sanchis Closa A
    Rev Esp Enferm Dig; 1991 Nov; 80(5):356. PubMed ID: 1768482
    [No Abstract]   [Full Text] [Related]  

  • 13. [Acute hepatitis caused by erythromycin esters (propionate and ethylsuccinate)].
    Paliard P; Stremsdoerfer N; Moindrot H
    Gastroenterol Clin Biol; 1983 Jan; 7(1):100-1. PubMed ID: 6601598
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Keeffe EB; Reis TC; Berland JE
    Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythromycin ethylsuccinate-induced cholestasis.
    Viteri AL; Greene JF; Dyck WP
    Gastroenterology; 1979 May; 76(5 Pt 1):1007-8. PubMed ID: 437404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythromycin ethylsuccinate, base and acistrate in the treatment of upper respiratory tract infection: two comparative studies of tolerability.
    Saloranta P; Roos L; Elonen E; Allonen H
    J Antimicrob Chemother; 1989 Sep; 24(3):455-62. PubMed ID: 2808197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-induced cholestasis].
    Pott G
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():73-5. PubMed ID: 7483722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythromycin ethylsuccinate hepatotoxicity.
    Sullivan D; Csuka ME; Blanchard B
    JAMA; 1980 Mar; 243(10):1074. PubMed ID: 6965509
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythromycin jaundice: diagnosis by an in vitro challenge test.
    Cooksley WG; Powell LW
    Aust N Z J Med; 1977 Jun; 7(3):291-3. PubMed ID: 269690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hepatotoxicity of erythromycin].
    García Buey L; García-Samaniego Rey J; González Estecha A; Pajares García JM
    Rev Clin Esp; 1989 Feb; 184(3):158. PubMed ID: 2785700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.